+34 679 490 537info@nanbiosis.com

Nanbiosis

U20. In Vivo Experimental Platform

Ciber bbn

U20. In Vivo Experimental Platform

U20. logo FVPP CIBBIM-Nanomedicina Vall d'HebronVall d´Hebrón_U20,U18

Order request

Description

Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.

This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.

Active projects

TitleFundin: OrganismCall: Funding source Role
ICTS-2017-10-CIBER-2Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo ExperimentMinisterio de Economía, Industria y Competitividad (MINECO)Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)Coordinator
GA: 720942SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-FabryUnión Europea (Comisión Europea)H2020-NMBP-2016-2017Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
RTC-2014-2207-1TERARMET: Development of therapies for the treatment of rare congenital metabolic diseasesMINECOParticipant

Publications

2016

  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
  • Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.

News U20

22 Nov

Lysosomal Rare Disorders: Focus on Fabry Disease

Last November 19, Vall d’Hebron held a seminar  on Lysosomal Rare Disorders: Focus on Fabry Disease as  part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the  second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]

08 Nov

Update and improvement of unit 20 of NANBIOSIS

NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Simó Schwartz and Dr. Ibane Ibasolo, has been recently updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020.  These update and improvement include: DLS meassurement system, a fluorimeter and a waterbath for specific activity assays. The fine characterization of the size and size distribution of nanoparticles is essential for the right understanding of their in vivo behavior. The incorporation of this service to the U20 allows the determination of the drug/fluorophore loading/activity of the drug delivery systemistered in vivo, a good quality[...]

17 Aug

Biodistribution, safety and efficacy studies of pharmacological release nanotechnological systems

Ibane Abásolo, Scientific Coordinator of NANBIOSIS U20, explains in this video the studies of biodistribution, safety and efficacy of nanotechnological systems of pharmacological liberation that are developed in this unit and , overall, their expertise and differentiation in the sector in the evaluation of nanosystems (with certification ISO 901-2015)[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanis[...]

11 Jun

NANBIOSIS Unit 20 expands its equipments and capabilities

NANBIOSIS U20- In Vivo Experimental Platform, led by Dr Simó Schwartz and Dr. Ibane Ibasolo, has recently added new equipment as a result of its participation in the project FICTS1420-20, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020. The new equipment is a Coagulometer (Diagnostica Stago STart® 4 Hemostasis Analyzer) used for measuring the  plasma coagulation time upon incubation with different stimulators (PT, APTT, Fibrinogen, D-dimer (quantitative), Thrombin time, Reptilase time etc.) the use o f this equipment will  allow the Unit to test the hemocompatibility of novel nanomedicines in development.[...]

05 Jun

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds. Also CSIC (The State Agency Superior Council of[...]

11 May

Fabry disease awareness month, April

The Fabry International Network (FIN) association established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry Disease is one of several dozen Lysosomal Storage Disorders that interfere with the body’s ability to break down specific fatty substances. It is a rare disease and because the rate of occurrence is less than 1 in 200,000, it is considered as one of the many “Orphan” diseases. It is more common in women, but it occurs with greater severity in men. Fabry disease is a metabolic[...]

07 May

The EVO-NANO project will allow testing the behavior of nanoparticles within a tumor

The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies)  within the Horizon 2020 program. The EVO-NANO project aims to develop a virtual simulator, called NanoDoc, which will allow testing the behavior of nanoparticles within a tumor and with other nanoparticles. It is a multidisciplinary project that will develop a consortium of European research centers with the aim of creating a platform available to everyone and at the forefront of Nanomedicine that facilitates the rapid development and testing of new treatments against cancer. “It will become an evolutiv[...]

U20-In Vivo Experimental Unit
Read More

U25. NMR: Biomedical Applications I

Ciber bbn

U25. NMR: Biomedical Applications I

  • Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
  • Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
  • Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
  • Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 814 126
  • Web: GABRMN-UAB seRMN-UAB

UAB

Order request

Description

The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) (http://sermn.uab.cat/) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB . This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN) (http://gabrmn.uab.es/), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.

The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.

The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.

The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Publications

2016

  • Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
  • Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
  • Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
  • Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.

News U25

04 Nov

Preclinical Study for Brain Tumor with Novel Contrast Agents for MRI

Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of  U25 of NANBIOSIS, NMR: Biomedical Applications I  have participated in the research published by ACS Applied Materials & Interfaces Journal  that include a preclinical study carried for brain Tumor. Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to  design magnetic resonance imaging (MRI) contrast agents (CAs) wit[...]

24 May

Nosological images of response to therapy based on metabolomic information by magnetic resonance

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I. is givin a talk about “Nosological images of response to therapy based on metabolomic information by magnetic resonance: a step beyond the standard image” next June 6, on Barcelona. According to Dr. Candiota, “The reliable characterization of the treatment response in glioblastoma (GB) is a key factor in improving the survival and prognosis of patients. Image (MRI) and spectroscopic image (MRSI) by magnetic resonance respectively provide morphological and metabolotic profiles of GB, but in general they are not as robust to produce surrogate biomarkers in response to short-term[...]

20 Mar

New book coauthored by Scientists of @NANBIOSIS U25 on Preclinical MRI

Silvia Lope-Piedrafita and Nuria Arias Ramos, Scientists of NANBIOSIS U25 NMR: Biomedical Applications I, have participated as co-authors in chapters of the book “Preclinical MRI – Methods and Protocols“. Editors: María Luisa García Martín y Pilar López Larrubia. This book, also co-authored by other researchers of CIBER-BBN, as Guadalupe Soria y Raul Tudela,  is organized into 7 parts : -Part 1 covers the basics of MRI physics, relaxation, image contrast, and main acquisition sequences; -Part 2 describes methodologies for diffusion, perfusion, and functional imaging; -Part 3 looks at in vivo spectroscopy; -Part 4 explores special MRI techniques that are less known in the field; -Parts 5 and[...]

19 Mar

Ana Paula Candiota member of the Panel of experts from the Autonomous University of Barcelona.

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I, is now part of the Panel of experts from the Autonomous University of Barcelona. This panel aims to offer their knowledge and experience to the media in case they have questions on specific issues.[...]

16 Nov

Posters presentation by NANBIOSIS Units in CIBER-BBN ANNUAL CONFERENCE 2017

Last 13 and 14 of November, CIBER-BBN  has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and  Paolo Saccardo as Coordinator (in the picture): Posters: U1. Protein Production Platform (PPP): Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José[...]

15 Feb

Unit 25 of NANBIOSIS and the research field of Protein Kinase CK2. 

Ana Paula Candiota and Carles Arús, Scientific Coordinator and Scientific Director of Unit 25 of NANBIOSIS, jointly with other GABRMN members, have recently published an interesting article in the journal Pharmaceuticals, (Special Issue An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2). This article  is also co-authored by scientifics of a research group with renowned prestige in CK2 research field, the Protein Phosphorylation group, del Dipartimento di scienze biomediche (Università degli Studi di Padova). This publication describes a study with the preclinical glioblastoma (GB) model and its treatment, centered in exploring the potential of[...]

01 Feb

MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM
MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM

Nuria Arias Ramos from GABRMN-UAB, research group coordinator of Unit 25 of NANBIOSIS, presented on January 30th, an oral communication at the youngSMIN | young Spanish Molecular Imaging Network Meeting. The title of the communication is “Multi slice MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM”, written by Nuria Arias-Ramos, SilviaLope-Piedrafita, Victor Mocioiu, Margarida Julià-Sapé, Carles Arús and Ana Paula Candiota. The work is basically centered in extending the preliminary GABRMN study based on MRSI  acquired in a preclinical glioblastoma (GB), both under treatment and control, with pattern recognition and source extraction for noninvasive therapy[...]

21 Dec

NANBIOSIS lecturers in B-Debate Imaging for Life. From Molecules to Diagnostics and Therapy
NANBIOSIS lecturers in B-Debate Imaging for Life. From Molecules to Diagnostics and Therapy

Last November took place in CosmoCaixa, Barcelona, the B-Debate Days Imaging for Life. Molecules from Diagnostics and Therapy. The event, organized by B·Debate (an initiative of Biocat and “la Caixa” Foundation), IBB and LJS, was focussed on Biomolecular Imaging, with emphasis on molecular, cellular, tissular and small animal research, as well as biomedical applications, including noninvasive diagnostics, image guided surgery, multimodal imaging and theranostics. Scientists of NANBIOIS Unit 20 and 25 were invited to participate as guest lecturers: -Simó Schwartz, Scientific Director of Unit 20: New bioluminescent models to target cancer stem cells with nanomedicine. -Ana Paula Candiota, Scientific Coordinator of[...]

U25-NMR Biomedical Applications I
Read More